Table 3.

Effect of CE/BZA on abdominal adipose and skeletal muscle gene expression¹

	Post-Treatment Outcomes		p-value
	Placebo	CE/BZA
Abdominal Adipose Tissue
Acyl-coenzyme A oxidase (ACOX1)	0.82 ± 0.98	1.32 ± 0.30	0.44
Adhesion G protein-coupled receptor E1 (ADGRE1)	0.95 ± 0.43	1.14 ± 0.23	0.53
Adiponectin (ADIPOQ)	0.50 ± 0.22	1.22 ± 0.33	0.02
Adrenoceptor beta 3 (ADRB3)	6.59 ± 10.44	2.20 ± 1.38	0.51
Chemokine ligand 2 monocyte chemotactic protein 1 (CCL2 MCP1)	1.23 ± 0.73	1.32 ± 0.26	0.85
Cell death effector-A (CDEA)	0.88 ± 0.31	1.61 ± 1.03	0.22
Iodothyronine deiodinase 2 (DIO2)	20.07 ± 23.20	1.97 ± 0.89	0.24
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)	0.98 ± 0.44	1.24 ± 0.30	0.43
Fatty-acid synthase (FAS)	1.78 ± 0.90	3.46 ± 2.55	0.27
Hypoxia-inducible factor 1-alpha (HIF1A)	1.47 ± 2.07	1.49 ± 0.60	0.99
Interleukin 6 (IL-6)	2.55 ± 0.76	2.14 ± 1.41	0.64
Leptin (LEP)	0.54 ± 0.41	1.22 ± 0.37	0.07
Lipase E (LIPE)	0.47 ± 0.24	0.97 ± 0.24	0.04
Lipoprotein lipase (LPL)	0.84 ± 0.96	1.11 ± 0.33	0.66
Peroxisome proliferator-activated receptor gamma (PPARG)	0.55 ± 0.42	1.19 ± 0.22	0.07
PPARG coactivator 1-alpha (PPARGC1A)	1.94 ± 2.65	1.75 ± 0.26	0.91
Solute carrier family 2 member 1 (SLC2A1, GLUT1)	0.78 ± 0.44	1.05 ± 0.18	0.37
Tumor necrosis factor (TNF)	0.75 ± 0.74	1.15 ± 1.33	0.63
Uncoupling protein 1 (UCP1)	19.02 ± 20.10	2.09 ± 0.74	0.21
Vascular endothelial growth factor-A (VEGFA)	0.60 ± 0.58	0.99 ± 0.23	0.33
Skeletal Muscle Tissue
Acetyl-CoA carboxylase 1 (ACACA)	1.42 ± 0.44	1.26 ± 0.20	0.60
Dynamin-1-like protein (DNM1L)	1.20 ± 0.18	1.24 ± 0.17	0.75
Estrogen receptor 1 (ESR1)	1.23 ± 0.23	0.90 ± 0.15	0.09
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)	1.00 ± 0.17	1.19 ± 0.13	0.17
Glutathione peroxidase 3 (GPX3)	1.39 ± 0.33	0.93 ± 0.09	0.07
Hypoxia-inducible factor 1-alpha (HIF1A)	1.17 ± 0.46	1.08 ± 0.43	0.81
Mitochondrially encoded cytochrome C oxidase I (MT-CO1)	0.95 ± 0.42	1.17 ± 0.30	0.49
Mitochondrially encoded cytochrome C oxidase II (MT-CO3)	0.69 ± 0.21	1.30 ± 0.61	0.11
Mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 1 (MT-ND1)	0.88 ± 0.32	0.86 ± 0.15	0.91
Mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 4 (MT-ND4)	0.91 ± 0.38	1.00 ± 0.23	0.73
Polymerase gamma (POLG1)	2.70 ± 3.11	1.02 ± 0.17	0.40
Mitochondrial RNA polymerase (POLMRT)	0.98 ± 0.23	1.31 ± 0.57	0.33
Peroxisome proliferator-activated receptor delta (PPARD)	1.28 ± 0.19	1.08 ± 0.04	0.14
PPARG coactivator 1-alpha (PPARGC1A)	0.97 ± 0.29	0.81 ± 0.14	0.44
Protein kinase AMP-activated non-catalytic subunit gamma 3 (PRKAG3)	1.40 ± 0.46	1.18 ± 0.31	0.51
Regulator of calcineurin 1 (RCAN1)	1.00 ± 0.23	1.07 ± 0.14	0.68
Solute carrier family 2 member 4 (SLC2A4)	1.42 ± 0.46	1.05 ± 0.17	0.25

Abbreviations: CE/BZA, conjugated estrogens/bazedoxifene.

¹Estimates of means±SD are listed for all post-treatment outcomes. p-values denote treatment-differences following adjustment for crossover design (treatment, order of treatment).